US Edition
Mabwell’s Mailisheng receives NMPA marketing approval
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Mabwell’s Mailisheng receives NMPA marketing approval
The company’s wholly owned subsidiary T-mab developed the drug. It is Mabwell’s first commercialised innovative drug, and the first introduced granulocyte colony-stimulating factor (G-CSF) developed with albumin long-acting The post Mabwell’s Mailisheng receives NMPA marketing approval appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
